Amneal Pharmaceuticals is projected to report Q2 2026 consensus revenue of $762.5 million and EPS of $0.24, with the current stock price of $14.12 sitting below the average analyst target of $16.80.
The primary focus for investors this quarter is the rapid scaling of the company’s biosimilars segment as it attempts to capture greater share in the ophthalmology and oncology markets.
Growth is being driven by a robust pipeline of complex generics and the continued commercial success of the Specialty division's core products like Rytary. Analysts expect these high-margin segments to offset traditional generic pricing pressure and improve overall EBITDA margins.